Search alternatives:
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
stem decrease » step decrease (Expand Search), sizes decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a large » _ large (Expand Search)
has a » has _ (Expand Search), had a (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
stem decrease » step decrease (Expand Search), sizes decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a large » _ large (Expand Search)
has a » has _ (Expand Search), had a (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>"
Published 2025“…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". The following acronyms included in the CSV file are defined as follows: Hbt is total hemoglobin, Art is artery region, DV is draining vein region, WV is whisker vein region, SEM is standard error mean, TS is time series, max peak is maximum peak, min peak is minima, AUC is area under the curve, WT is wild-type, AD is Alzheimer's disease, ATH is atherosclerosis and MIX is mixed AD/atherosclerosis. …”
-
9
-
10
Table 3_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.xlsx
Published 2025“…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”
-
11
Table 1_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx
Published 2025“…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”
-
12
Table 2_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx
Published 2025“…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”
-
13
Data Sheet 1_Persistent lymphopenia after kidney transplantation: increased mortality and decreased homeostatic mechanisms.docx
Published 2025“…Mass cytometry immunophenotyping at 3 years showed that B cells, NK cells and all T cell subsets (CD4, CD8, naïve, memory, etc.) decreased with decreasing lymphocyte counts. This included fewer recent thymic emigrants, naïve T cells, and stem-cell like memory T cells (T<sub>SCM</sub>), suggesting an impaired homeostasis of peripheral T cells. …”
-
14
-
15
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”
-
16
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”
-
17
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”
-
18
-
19
-
20